[Effect of the intravenous administration of finoptin on coronary venous blood flow in patients with ischemic heart disease].
Intravenous finoptin (verapamil), 10 mg, was tested for effects on the coronary venous blood flow by probing the coronary sinus and great vein of the heart and performing atrial pacing in 24 patients with ischemic heart disease and eukinetic central hemodynamics. In persons who had had initial high blood flow in the coronary sinus, the agent was found to induce resting coronary venous blood flow changes which were inadequate for its demand and during cardiac pacing; whereas in patients with mean initial venous blood flow values, finoptin enabled myocardial oxygen consumption to be provided both in the region of non-infarcted myocardium and in the ischemic area.
Uchaĭkina
L V
LV
Vakhliaev
V D
VD
D003326:Coronary Circulation / Q000187:drug effects* / Q000502:physiology; D003327:Coronary Disease / Q000188:drug therapy* / Q000503:physiopathology; D003331:Coronary Vessels / Q000187:drug effects* / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D007275:Injections, Intravenous; D007277:Injections, Jet; D008875:Middle Aged; D014680:Veins / Q000187:drug effects / Q000503:physiopathology; D014700:Verapamil / Q000008:administration & dosage*
D014700:Verapamil
Vliianie vnutrivennogo vvedeniia finoptina na sostoianie koronarnogo venoznogo krovotoka u bol'nykh ishemicheskoĭ bolezn'iu serdtsa.